Neri S, Pistone G, Saraceno B, et al
45 Some individuals get caught in a cycle of not eating due to nausea, which worsens the symptoms, which then further reduces the likelihood of eating
Medicare does not cover GLP-1 medications for weight loss under Part D, although the Medicare Bridge Program launched July 1, 2026 provides $50 per month for Wegovy pen, Wegovy pill, Zepbound KwikPen, and Foundayo for eligible Medicare beneficiaries with BMI 27 and above and an obesity-related comorbidity, running through December 31, 2027 (PeptideDeck)
Efficacy for glycemic control : Clinical trials of semaglutide (SUSTAIN program) have demonstrated hemoglobin A1c reductions of 1.5-2.0% in patients with type 2 diabetes, with many patients achieving A1c levels below 7%
Some people may need to stay on a maintenance dose of a GLP-1 Receptor Agonist for a while to be able to manage their weight effectively, but as long as side effects are minimal or tolerable, this should be manageable under the supervision of a prescriber
